<DOC>
	<DOCNO>NCT00844987</DOCNO>
	<brief_summary>The main aim study comparison serum plasma concentration VEGF ( Vascular Endothelial Growth Factor ) , HGF ( Hepatocyte Growth Factor ) PDGF ( Platelet Derived Growth Factor ) marker myocardial injury troponin I , hsCRP , CK-MB NT-proBNP assess patient first episode acute coronary syndrome ( ACS ) live estimation assume value VEGF , HGF PDGF prognosis cardiovascular complication 3 month follow especially respect myocardial infarction ( MI ) , exacerbation angina , reintervention ( PTCA , CABG ) , symptoms heart failure , stroke , rehospitalization due cardiovascular reason death . The dynamic change serum plasma concentration growth factor comparison value myocardial injury marker check . For realization purpose study biochemical measurement perform twice i.e . admission hospital 24h later . Area myocardial injury estimate echocardiography examination .</brief_summary>
	<brief_title>Vascular Endothelial Growth Factor ( VEGF ) , Platelet Derived Growth Factor ( PDGF ) , Hepatocyte Growth Factor ( HGF ) Patients With Acute Coronary Syndrome ( ACS )</brief_title>
	<detailed_description>In recent year several biomarkers investigate use diagnostic risk stratification patient symptoms acute coronary syndrome . Troponins preferred marker myocardial injury due high specificity sensitivity make superior traditional cardiac enzyme CK CK-MB . Elevated level NT-proBNP marker heart failure strongly associate increased mortality rate . This study invent search new sensitive indicator myocardial injury predictor bad outcome patient symptoms ACS especially useful difficult diagnostic therapeutic situation . The study perform patient first episode ACS life eligible coronary angiography eventually PCI . All subject agree participate study informed nature purpose . Patients , due symptom accord ESC guideline refer coronary angiography , primary PCI , surgery revascularisation pharmacological treatment . Inclusion study influence type treatment . The measurement VEGF , HGF , PDGF , troponin I , hsCRP , CK-MB NT-proBNP assess twice i.e . soon possible admission hospital 24h first measurement . For estimation change concentration growth factor time patient multiple assessment perform ( 9 measurement first 24h 1 discharge hospital ) . In healthy volunteer ( 10 20 subject ) one , control measurement HGF perform . Three day ACS symptom appear , leave ventricular function determine echocardiography . Scheduled control visit perform 3 month follow . The demographic clinical data , duration chest pain , result 12 lead ECG , angiographic finding , haemodynamic description cardiac function ( parameter echocardiography ventriculography ) , type invasive revascularisation result perform measurement examination undergo single multivariable statistical analysis . Additionally , accord clinical angiographic finding statistic analysis specify either : subgroup patient `` major myocardial injury '' comprise patient anterior antero-lateral myocardial infarction ( MI ) occlusion significant leave anterior descending ( LAD ) branch stenosis and/or multivessel disease , subgroup patient `` moderate myocardial injury '' consist patient inferior and/or posterior MI singlevessel disease LAD , subgroup patient `` minor myocardial injury '' include patient NSTE-ACS ( Non-ST-Segment Elevation ACS ) without significant increase myocardial injury marker .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1. typical chest pain ; 2 . ST segment elevation depression ECG ; 3. indication coronary angiography ; necessary PCI 4 ) sign inform consent . 1. known past history myocardial infarction ; 2. sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>PDGF</keyword>
	<keyword>HGF</keyword>
	<keyword>VEGF</keyword>
	<keyword>ACS</keyword>
	<keyword>marker myocardial injury</keyword>
	<keyword>Vascular Endothelial Growth Factor</keyword>
	<keyword>Hepatocyte Growth Factor</keyword>
	<keyword>Platelet Derived Growth Factor</keyword>
	<keyword>Strategies ACS</keyword>
</DOC>